Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Novel Oral AntiCoagulants (NOAC) Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Direct Thrombin Inhibitors
      • 1.3.3 Direct Factor Xa Inhibitors
    • 1.4 Market Segment by Application
      • 1.4.1 Global Novel Oral AntiCoagulants (NOAC) Market Share by Application (2019-2025)
      • 1.4.2 Deep Vein Thrombosis (DVT)
      • 1.4.3 Pulmonary Embolism
      • 1.4.4 Acute Coronary Syndrome
      • 1.4.5 Hemodialysis
      • 1.4.6 Others
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Novel Oral AntiCoagulants (NOAC) Market Size
      • 2.1.1 Global Novel Oral AntiCoagulants (NOAC) Revenue 2014-2025
      • 2.1.2 Global Novel Oral AntiCoagulants (NOAC) Sales 2014-2025
    • 2.2 Novel Oral AntiCoagulants (NOAC) Growth Rate by Regions
      • 2.2.1 Global Novel Oral AntiCoagulants (NOAC) Sales by Regions 2014-2019
      • 2.2.2 Global Novel Oral AntiCoagulants (NOAC) Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Novel Oral AntiCoagulants (NOAC) Sales by Manufacturers
      • 3.1.1 Novel Oral AntiCoagulants (NOAC) Sales by Manufacturers 2014-2019
      • 3.1.2 Novel Oral AntiCoagulants (NOAC) Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Novel Oral AntiCoagulants (NOAC) Revenue by Manufacturers (2014-2019)
      • 3.2.2 Novel Oral AntiCoagulants (NOAC) Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Novel Oral AntiCoagulants (NOAC) Market Concentration Ratio (CR5 and HHI)
    • 3.3 Novel Oral AntiCoagulants (NOAC) Price by Manufacturers
    • 3.4 Key Manufacturers Novel Oral AntiCoagulants (NOAC) Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Novel Oral AntiCoagulants (NOAC) Market
    • 3.6 Key Manufacturers Novel Oral AntiCoagulants (NOAC) Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Direct Thrombin Inhibitors Sales and Revenue (2014-2019)
      • 4.1.2 Direct Factor Xa Inhibitors Sales and Revenue (2014-2019)
    • 4.2 Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Type
    • 4.3 Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Type
    • 4.4 Novel Oral AntiCoagulants (NOAC) Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Novel Oral AntiCoagulants (NOAC) Sales by Application

    6 United States

    • 6.1 United States Novel Oral AntiCoagulants (NOAC) Breakdown Data by Company
    • 6.2 United States Novel Oral AntiCoagulants (NOAC) Breakdown Data by Type
    • 6.3 United States Novel Oral AntiCoagulants (NOAC) Breakdown Data by Application

    7 European Union

    • 7.1 European Union Novel Oral AntiCoagulants (NOAC) Breakdown Data by Company
    • 7.2 European Union Novel Oral AntiCoagulants (NOAC) Breakdown Data by Type
    • 7.3 European Union Novel Oral AntiCoagulants (NOAC) Breakdown Data by Application

    8 China

    • 8.1 China Novel Oral AntiCoagulants (NOAC) Breakdown Data by Company
    • 8.2 China Novel Oral AntiCoagulants (NOAC) Breakdown Data by Type
    • 8.3 China Novel Oral AntiCoagulants (NOAC) Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Novel Oral AntiCoagulants (NOAC) Breakdown Data by Company
    • 9.2 Rest of World Novel Oral AntiCoagulants (NOAC) Breakdown Data by Type
    • 9.3 Rest of World Novel Oral AntiCoagulants (NOAC) Breakdown Data by Application
    • 9.4 Rest of World Novel Oral AntiCoagulants (NOAC) Breakdown Data by Countries
      • 9.4.1 Rest of World Novel Oral AntiCoagulants (NOAC) Sales by Countries
      • 9.4.2 Rest of World Novel Oral AntiCoagulants (NOAC) Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Johnson & Johnson
      • 10.1.1 Johnson & Johnson Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Novel Oral AntiCoagulants (NOAC)
      • 10.1.4 Novel Oral AntiCoagulants (NOAC) Product Introduction
      • 10.1.5 Johnson & Johnson Recent Development
    • 10.2 Bristol-Myers Squibb
      • 10.2.1 Bristol-Myers Squibb Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Novel Oral AntiCoagulants (NOAC)
      • 10.2.4 Novel Oral AntiCoagulants (NOAC) Product Introduction
      • 10.2.5 Bristol-Myers Squibb Recent Development
    • 10.3 Boehringer Ingelheim
      • 10.3.1 Boehringer Ingelheim Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Novel Oral AntiCoagulants (NOAC)
      • 10.3.4 Novel Oral AntiCoagulants (NOAC) Product Introduction
      • 10.3.5 Boehringer Ingelheim Recent Development
    • 10.4 Sanofi
      • 10.4.1 Sanofi Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Novel Oral AntiCoagulants (NOAC)
      • 10.4.4 Novel Oral AntiCoagulants (NOAC) Product Introduction
      • 10.4.5 Sanofi Recent Development
    • 10.5 Daiichi Sankyo
      • 10.5.1 Daiichi Sankyo Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Novel Oral AntiCoagulants (NOAC)
      • 10.5.4 Novel Oral AntiCoagulants (NOAC) Product Introduction
      • 10.5.5 Daiichi Sankyo Recent Development
    • 10.6 Armatheon
      • 10.6.1 Armatheon Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Novel Oral AntiCoagulants (NOAC)
      • 10.6.4 Novel Oral AntiCoagulants (NOAC) Product Introduction
      • 10.6.5 Armatheon Recent Development
    • 10.7 Aspen
      • 10.7.1 Aspen Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Novel Oral AntiCoagulants (NOAC)
      • 10.7.4 Novel Oral AntiCoagulants (NOAC) Product Introduction
      • 10.7.5 Aspen Recent Development
    • 10.8 AstraZeneca
      • 10.8.1 AstraZeneca Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Novel Oral AntiCoagulants (NOAC)
      • 10.8.4 Novel Oral AntiCoagulants (NOAC) Product Introduction
      • 10.8.5 AstraZeneca Recent Development
    • 10.9 Bayer
      • 10.9.1 Bayer Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Novel Oral AntiCoagulants (NOAC)
      • 10.9.4 Novel Oral AntiCoagulants (NOAC) Product Introduction
      • 10.9.5 Bayer Recent Development
    • 10.10 Cellceutix
      • 10.10.1 Cellceutix Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Novel Oral AntiCoagulants (NOAC)
      • 10.10.4 Novel Oral AntiCoagulants (NOAC) Product Introduction
      • 10.10.5 Cellceutix Recent Development
    • 10.11 Cosmo Pharmaceuticals
    • 10.12 CSL Behring
    • 10.13 Eisai
    • 10.14 GSK
    • 10.15 Marathon Pharmaceuticals
    • 10.16 Ockham Biotech
    • 10.17 Perosphere

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Novel Oral AntiCoagulants (NOAC) Sales Channels
      • 11.2.2 Novel Oral AntiCoagulants (NOAC) Distributors
    • 11.3 Novel Oral AntiCoagulants (NOAC) Customers

    12 Market Forecast

    • 12.1 Global Novel Oral AntiCoagulants (NOAC) Sales and Revenue Forecast 2019-2025
    • 12.2 Global Novel Oral AntiCoagulants (NOAC) Sales Forecast by Type
    • 12.3 Global Novel Oral AntiCoagulants (NOAC) Sales Forecast by Application
    • 12.4 Novel Oral AntiCoagulants (NOAC) Forecast by Regions
      • 12.4.1 Global Novel Oral AntiCoagulants (NOAC) Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Novel Oral AntiCoagulants (NOAC) Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      In 2019, the market size of Novel Oral AntiCoagulants (NOAC) is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Novel Oral AntiCoagulants (NOAC).

      This report studies the global market size of Novel Oral AntiCoagulants (NOAC), especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Novel Oral AntiCoagulants (NOAC) sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Johnson & Johnson
      Bristol-Myers Squibb
      Boehringer Ingelheim
      Sanofi
      Daiichi Sankyo
      Armatheon
      Aspen
      AstraZeneca
      Bayer
      Cellceutix
      Cosmo Pharmaceuticals
      CSL Behring
      Eisai
      GSK
      Marathon Pharmaceuticals
      Ockham Biotech
      Perosphere

      Market Segment by Product Type
      Direct Thrombin Inhibitors
      Direct Factor Xa Inhibitors

      Market Segment by Application
      Deep Vein Thrombosis (DVT)
      Pulmonary Embolism
      Acute Coronary Syndrome
      Hemodialysis
      Others

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Novel Oral AntiCoagulants (NOAC) status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Novel Oral AntiCoagulants (NOAC) manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Novel Oral AntiCoagulants (NOAC) are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now